Frontiers in Psychiatry
May 12, 2023
Grace Blest‐hopley, Ben H Amit, Aisling O'Neill et al.
Editorial on the Research Topic Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders
International Journal of Environmental Research and Public Health
January 19, 2023
Koen Ponnet, Bert Hauspie, Nicky Dirkx et al.
21 citations
EDM event attendees are a high-risk population for substance use and associated adverse effects. The aim of this study was to examine substance use at EDM events, focusing on associations between attendance motives and substance use. Sociodemographic characteristics, event specifics, past-year use, and attendance motives were assessed through an online survey. Participants were 1345 Belgian EDM...
Frontiers in Pharmacology
2023
Moniek Schouten, Sebastiaan Dalle, Dante Mantini et al.
Cannabidiol (CBD) is a naturally occurring non-psychoactive cannabinoid found in Cannabis sativa, commonly known as cannabis or hemp. Although currently available CBD products do not meet the safety standards of most food safety authorities to be approved as a dietary supplement or food additive, CBD has been gaining widespread attention in recent years due to its various potential health...
Frontiers in Neuroscience
2023
Michael J Wesley, Joshua A Lile
Psychotropic drugs and transcranial magnetic stimulation (TMS) are effective for treating certain psychiatric conditions. Drugs and TMS have also been used as tools to explore the relationship between brain function and behavior in humans. Combining centrally acting drugs and TMS has proven useful for characterizing the neural basis of movement. This combined intervention approach also holds...
Pharmacology, Biochemistry, and Behavior
January 2023
Carley Marie Huffstetler, Brigitte Cochran, Camilla Ann May et al.
The behavioral effects of cannabidiol (CBD) are understudied, but are important, given its therapeutic potential and widespread use as a natural supplement. The objective of this study was to test whether a single injection of CBD affected anxiety-like or attention-like behavior, or memory in wildtype mice or mice with reported trait anxiety due to a targeted gene-deletion in a...
Neurobiology of Disease
2023
Marta Barrera-Conde, Emma Veza-Estévez, Maria Gomis-Gonzalez et al.
Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that has emerged as a key regulator of neurotransmission in complex cognitive processes. Its expression is altered in treated schizophrenia patients, and cannabinoids modulate CDK5 levels in the brain of rodents. However, the role of this kinase, and its interaction with cannabis use in first-episode psychosis (FEP) patients is still...
Integrative Cancer Therapies
2023
Leanna J Standish, Sonia M Malani, Ksenia Lynch et al.
5 citations
In 1991 the U.S. Congress mandated that the National Institutes of Health (NIH) form the Office of Alternative Medicine to study alternative medical therapies, especially in oncology care. Shortly after, the National Cancer Institute (NCI) created its own division of complementary and alternative medicine (Office of Complementary and Alternative Medicine). At the genesis of the field 30 years...
Vertex Revista Argentina de Psiquiatría
October 10, 2022
Federico Pavlovsky, Rafael Groisman, Ana Karina Hurtado et al.
Addictions are one of the most important health problems worldwide. Within these disorders, cannabis is one of the psychoactive substances with more burden of morbidity and mortality worldwide. The actual knowledge about the effectiveness of treatments for cannabis use disorders is unsatisfactory. This review aims to explore the evidence on cannabidiol for the treatment of cannabis use...
October 10, 2022
Malcolm Hopwood
Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new therapies for mental illness were previously considered unthinkable — party drugs including ketamine, medicinal cannabis and psychedelics like MDMA, psilocybin and DMT. With mental health disorders a growing cause of disability […]
Experimental and Clinical Psychopharmacology
September 1, 2022
Julie A E Christensen, David C. Fipps, J Michael Bostwick
4 citations
Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after use has ceased. The most common substances precipitating HPPD, lysergic acid diethylamide (LSD) and psilocybin, are posited to do so via damage to serotonergic neurons involved in vision. Mr. N is a 37-year-old with a history of alcohol, cannabis,...